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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
fructo-oligosaccharides (FOS) and decreasing potentially pathogenic 
gastro-intestinal microorganisms (ID 781) pursuant to Article 13(1) of 
Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,
 
3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in 
relation to fructo-oligosaccharides and decreasing potentially pathogenic gastro-intestinal 
microorganisms. The scientific substantiation is based on the information provided by the Member 
States in the consolidated list of Article 13 health claims and references that EFSA has received from 
Member States or directly from stakeholders. 
The food constituent that is the subject of the health claim is fructo-oligosaccharides. The Panel 
considers that fructo-oligosaccharides are sufficiently characterised in relation to the claimed effect. 
The claimed effect is ―beneficial effect on intestinal microflora, gut integrity, digestion‖. The target 
population is assumed to be the general population. The Panel considers that the claimed effect, in the 
context of decreasing potentially pathogenic gastro-intestinal microorganisms, might be a beneficial 
physiological effect. 
No human studies from which conclusions could be drawn for the scientific substantiation of the claim 
were provided. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of fructo-oligosaccharides and decreasing potentially 
pathogenic gastro-intestinal microorganisms. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1568, adopted on 08 April 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
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Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve as 
clarification to the originally provided information. The information provided in the consolidated list 
for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent (ID 781) 
The food constituent that is the subject of the health claim is fructo-oligosaccharides (FOS). 
FOS constitute a class of saccharide oligomers consisting of short chains of fructose molecules. FOS 
are manufactured by enzymatic or chemical degradation of inulin, or by enzymatic elongation of 
sucrose. Different types of FOS mixtures are available on the market. 
This opinion refers to FOS from both inulin and sucrose. 
The Panel considers that the food constituent, fructo-oligosaccharides, which is the subject of the 
health claim, is sufficiently characterised in relation to the claimed effect. 
2. Relevance of the claimed effect to human health (ID 781) 
The claimed effect is ―beneficial effect on intestinal microflora, gut integrity, digestion‖. The Panel 
assumes that the target population is the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to increasing 
numbers of bacteria in the gut which are considered to be ―beneficial‖. 
The numbers/proportions of bacterial groups which would constitute a ―healthy balanced‖ 
gastro-intestinal flora have not been established. Increasing the number of any group of 
microorganisms in the gut, including lactobacilli and/or bifidobacteria, is not in itself considered to be 
a beneficial physiological effect. 
The Panel considers that the evidence provided does not establish that increasing numbers of 
gastro-intestinal microorganisms is a beneficial physiological effect. 
The Panel considers that the claimed effect, in the context of decreasing potentially pathogenic 
gastro-intestinal microorganisms, might be a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect (ID 781) 
Among the references provided in relation to this claim were textbooks and narrative reviews which 
did not provide original data for the scientific substantiation of the claim. 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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Some of the human studies provided used food constituents other than FOS, or reported on health 
outcomes (e.g. beta-glucuronidase and reductase activity, faecal wet and dry weight, colonic crypt cell 
proliferation, and blood lipids) unrelated to the claimed effect. One conference report was not 
available to the Panel after every reasonable effort had been made to retrieve it. The Panel considers 
that no conclusions can be drawn from these references for the scientific substantiation of the claim.  
A number of human intervention studies focused on the effects of FOS on faecal bifidobacteria 
(Bouhnik et al., 1996; Bouhnik et al., 1999; Bouhnik et al., 2004; Kruse et al., 1999), or bifidobacteria 
together with other bacteria groups (e.g. lactobacilli, enterobacteria, Bacteroides, clostridia, 
fusobacteria, coliforms, Gram-positive cocci, Bacteroides-Prevotella group, Clostridium perfringens-
Clostridium histolyticum group, total anaerobes, and total aerobes) (Bouhnik et al., 2006; Bouhnik et 
al., 2007; Gibson et al., 1995; Kleessen et al., 1997; Rao, 2001; Tuohy et al., 2001). The Panel notes 
that the bacterial groups analysed in these studies are part of the commensal intestinal microbiota, and 
that no evidence was provided for the characterisation of any of these bacterial groups as pathogens. In 
four human studies the effects of FOS on Clostridium perfringens were investigated (Menne et al., 
2000; Mitsuoka et al., 1986; Mitsuoka et al., 1987; Tokunaga et al., 1993) but no information was 
provided about the pathogenicity of the bacterial strains studied. The Panel considers that no 
conclusions can be drawn from these references for the scientific substantiation of the claim. 
Human studies addressing outcomes such as faecal pH and short-chain fatty acid concentrations in 
faeces may provide information on the mechanisms by which the food constituent could exert the 
claimed effect, but are not sufficient per se to predict an effect of FOS on decreasing potentially 
pathogenic gastro-intestinal microorganisms.  
The Panel notes that no human studies from which conclusions could be drawn for the scientific 
substantiation of the claim were provided. 
The Panel considers that evidence provided in in vitro studies is not sufficient to predict the 
occurrence of an effect of FOS consumption on potentially pathogenic gastro-intestinal 
microorganisms in vivo in humans.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of fructo-oligosaccharides and decreasing potentially pathogenic gastro-intestinal 
microorganisms. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, fructo-oligosaccharides, which is the subject of the claim, is sufficiently 
characterised in relation to the claimed effect. 
 The claimed effect is ―beneficial effect on intestinal microflora, gut integrity, digestion‖. The 
target population is assumed to be the general population. Decreasing potentially pathogenic 
gastro-intestinal microorganisms might be a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
fructo-oligosaccharides and decreasing potentially pathogenic gastro-intestinal microorganisms. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1568). 
The scientific substantiation is based on the information provided by the Member States in the 
consolidated list of Article 13 health claims and references that EFSA has received from Member 
States or directly from stakeholders. 
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The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to a 
single food is scientifically pertinent. 
It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
                                                     
6 OJ L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific data, 
and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, 
dose-response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of the 
application for authorisation of health claims consistent criteria for the potential sources of scientific 
data. Such sources may not be available for all health claims. Nevertheless it will be relevant and 
important that EFSA comments on the availability and quality of such data in order to allow the 
regulator to judge and make a risk management decision about the acceptability of health claims 
included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not enough 
to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. Moreover, 
the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially affect identified 
functions in the body in a way which is relevant to health. Although an appreciation of the beneficial 
effect in relation to the nutritional status of the European population may be of interest, the presence or 
absence of the actual need for a nutrient or other substance with nutritional or physiological effect for 
that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic or 
cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of the 
body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which specifies 
this by using the word "flexibility". 
Fructo-oligosaccharides (FOS) and decreasing pathogenic gastro-intestinal microorganisms 
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The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore be 
specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings should 
be avoided. To this end, wordings like "strengthens your natural defences" or "contain antioxidants" 
should be considered as well as "may" or "might" as opposed to words like "contributes", "aids" or 
"helps".  
In addition, for functions affected by a large number of dietary factors it should be considered whether 
wordings such as "indispensable", "necessary", "essential" and "important" reflects the strength of the 
scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally accepted 
scientific evidence by taking into account the totality of the available scientific data, and by 
weighing the evidence. In this context EFSA is invited to comment on the nature and quality 
of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent 
to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
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 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to fructo-oligosaccharides, including conditions of use from 
similar claims, as proposed in the Consolidated List. 
ID Food or Food component Health Relationship Proposed wording 
781 Fructo-oligosaccharides Beneficial effect on 
intestinal microflora, gut 
integrity, digestion 
Helps maintain a healthy balance of 
beneficial bacteria, Promotes the 
positive balance of the intestinal 
flora, Maintains a healthy gut, 
Maintains a healthy intestinal 
environment, Stimulates the growth 
of bifidobacteria 
Conditions of use 
- 2 Gramm (g) g/Tag; FOS aus Sukrose 
- alle Personen 5 Gramm (g); 1,5 pro Portion täglich, mindestens 7 Tage; siehe 
http://www.gdch.de/strukturen/fg/lm/ag/ernaehrung/stellungnahmen/inulin.htm 
- Erwachsene; signifikante Menge im lebensmittel (mind. 3g / 100 g oder 100 kcal) 
- 5 Gramm (g) g/Tag 
- 8 Gramm (g) g/Tag 
- Daily Intake: 5g - 30g 
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GLOSSARY AND ABBREVIATIONS 
FOS  Fructo-oligosaccharides 
 
 
 
 
